Life Extension Blood Test Super Sale

Life Extension Magazine

Life Extension Magazine November 2013
Report  

Block Acid Reflux to Prevent Esophageal Problems!

By Kirk Stokel

References

  1. Available at: http://www.webmd.com/heartburn-gerd/guide/acid-reflux-symptoms. Accessed June 12, 2012.
  2. Available at: http://www.cancer.gov/cancertopics/pdq/treatment/esophageal/HealthProfessional/page1. Accessed June 12, 2012.
  3. Lagergren J, Bergstrom R, Lindgren A, Nyren O. Symptomatic gastroesophageal reflux as a risk factor for esophageal adenocarcinoma. N Engl J Med. 1999 Mar 18;340(11):825-31.
  4. Glenn TF. Esophageal cancer. Facts, figures, and screening. Gastroenterol Nurs. 2001 Nov-Dec;24(6):271-3.
  5. Available at: http://www.mdanderson.org/patient-and-cancer-information/cancer-information/cancer-types/esophageal-cancer/index.html. Accessed August 7, 2013.
  6. Lagergren J, Lagergren P. Recent developments in esophageal adenocarcinoma. CA Cancer J Clin. 2013 Jul;63(4):232-48.
  7. Ryan AM, Duong M, Healy L, et al. Obesity, metabolic syndrome and esophageal adenocarcinoma: epidemiology, etiology and new targets. Cancer Epidemiol. 2011 Aug;35(4):309-19
  8. Mandel KG, Daggy BP, Brodie DA, Jacoby HI. Review article: alginate-raft formulations in the treatment of heartburn and acid reflux. Aliment Pharmacol Ther. 2000 Jun;14(6):669-90.
  9. Washington N, Greaves JL, Iftikhar SY. A comparison of gastro-oesophageal reflux in volunteers assessed by ambulatory pH and gamma monitoring after treatment with either Liquid Gaviscon or Algicon Suspension. Aliment Pharmacol Ther. 1992 Oct;6(5):579-88.
  10. Washington N, Steele RJ, Jackson SJ, Washington C, Bush D. Patterns of food and acid reflux in patients with low-grade oesophagitis--the role of an anti-reflux agent. Aliment Pharmacol Ther. 1998 Jan;12(1):53-8.
  11. Chatfield S. A comparison of the efficacy of the alginate preparation, Gaviscon Advance, with placebo in the treatment of gastro-oesophageal reflux disease. Curr Med Res Opin. 1999;15(3):152-9.
  12. Bordin DS, Masharova AA, Firsova LD, Kozhurina TS, Safonova OV. Evaluation of action, efficacy, and onset dynamics of a single dose of alginates in patients with heartburn and GERD. Eksp Klin Gastroenterol. 2009 (4):77-85.
  13. McGlashan JA, Johnstone LM, Sykes J, Strugala V, Dettmar PW. The value of a liquid alginate suspension (Gaviscon Advance) in the management of laryngopharyngeal reflux. Eur Arch Otorhinolaryngol. 2009 Feb;266(2):243-51.
  14. Cooperative Oesophageal Group. Combination of cimetidine and alginic acid: an improvement in the treatment of oesophageal reflux disease. Gut. 1991 Jul;32(7):819-22.
  15. Washington N, Denton G. Effect of alginate and alginate-cimetidine combination therapy on stimulated postprandial gastro-oesophageal reflux. J Pharm Pharmacol. 1995 Nov;47(11):879-82.
  16. Poynard T, Vernisse B, Agostini H. Randomized, multicentre comparison of sodium alginate and cisapride in the symptomatic treatment of uncomplicated gastrooesophageal reflux. Aliment Pharmacol Ther. 1998 Feb;12(2):159-65.
  17. Dettmar PW, Sykes J, Little SL, Bryan J. Rapid onset of effect of sodium alginate on gastro-oesophageal reflux compared with ranitidine and omeprazole, and relationship between symptoms and reflux episodes. Int J Clin Pract. 2006 Mar;60(3):275-83.
  18. Available at: http://dailymed.nlm.nih.gov/dailymed/archives/fdaDrugInfo.cfm?archiveid=13266. Accessed June 12, 2012.
  19. Pouchain D, Bigard MA, Liard F, Childs M, Decaudin A, McVey D. Gaviscon® vs. omeprazole in symptomatic treatment of moderate gastroesophageal reflux. a direc31comparative randomised trial. BMC Gastroenterol. 2012;12:18.
  20. Reimer C, Bytzer P. Adverse events associated with long-term use of proton pump inhibitors. Ugeskr Laeger. 2012 Sep 24;174(39):2289-93.
  21. Giannini EG, Zentilin P, Dulbecco P, et al. A comparison between sodium alginate and magaldrate anhydrous in the treatment of patients with gastroesophageal reflux symptoms. Dig Dis Sci. 2006 Nov;51(11):1904-9.
  22. Beserra AM, Calegari PI, Souza Mdo C, et al. Gastroprotective and ulcer-healing mechanisms of ellagic acid in experimental rats. J Agric Food Chem. 2011 Jul 13;59(13):6957-65.
  23. Chatterjee A, Chatterjee S, Das S, Saha A, Chattopadhyay S, Bandyopadhyay SK. Ellagic acid facilitates indomethacin-induced gastric ulcer healing via COX-2 up-regulation. Acta Biochim Biophys Sin (Shanghai). 2012 May 24.
  24. Murakami S, Isobe Y, Kijima H, Nagai H, Muramatu M, Otomo S. Inhibition of gastric H+, K(+)-ATPase and acid secretion by ellagic acid. Planta Med. 1991 Aug;57(4):305-8.
  25. Iino T, Tashima K, Umeda M, et al. Effect of ellagic acid on gastric damage induced in ischemic rat stomachs following ammonia or reperfusion. Life Sci. 2002 Jan 25;70(10):1139-50.
  26. Chung JG. Inhibitory actions of ellagic acid on growth and arylamine N-acetyltransferase activity in strains of Helicobacter pylori from peptic ulcer patients. Microbios. 1998;93(375):115-27.
  27. Sachs G, Scott DR. Helicobacter pylori: Eradication or Preservation. F1000 Med Rep. 2012;4:7.
  28. Mandal S, Stoner GD. Inhibition of N-nitrosobenzylmethylamine-induced esophageal tumorigenesis in rats by ellagic acid. Carcinogenesis. 1990 Jan;11(1):55-61.
  29. Zafra-Stone S, Yasmin T, Bagchi M, Chatterjee A, Vinson JA, Bagchi D. Berry anthocyanins as novel antioxidants in human health and disease prevention. Mol Nutr Food Res. 2007 Jun;51(6):675-83.
  30. Alvarez-Suarez JM, Dekanski D, Ristic S, et al. Strawberry polyphenols attenuate ethanol-induced gastric lesions in rats by activation of antioxidant enzymes and attenuation of MDA increase. PLoS One. 2011;6(10):e25878.
  31. Carlton PS, Kresty LA, Siglin JC, et al. Inhibition of N-nitrosomethylbenzylamine-induced tumorigenesis in the rat esophagus by dietary freeze-dried strawberries. Carcinogenesis. 2001 Mar;22(3):441-6.
  32. Chen T, Yan F, Qian J, et al. Randomized phase II trial of lyophilized strawberries in patients with dysplastic precancerous lesions of the esophagus. Cancer Prev Res (Phila). 2012 Jan;5(1):41-50
  33. Kassem M, Eriksen EF, Melsen F, Mosekilde L. Antacid-induced osteomalacia: a case report with a histomorphometric analysis. J Intern Med . 1991 Mar;229(3):275-9.
  34. Krewski D, Yokel RA, Nieboer E, et al. Human health risk assessment for aluminium, aluminium oxide, and aluminium hydroxide. J Toxicol Environ Health B Crit Rev. 2007;10 Suppl 1:1-269.
  35. Ruscin JM, Page RL 2nd, Valuck RJ. Vitamin B(12) deficiency associated with histamine(2)-receptor antagonists and a proton-pump inhibitor. Ann Pharmacother. 2002 May;36(5):812-6
  36. Valuck RJ, Ruscin JM. A case-control study on adverse effects: H2 blocker or proton pump inhibitor use and risk of vitamin B12 deficiency in older adults. J Clin Epidemiol. 2004 Apr;57(4):422-8.
  37. Oh S. Proton pump inhibitors--uncommon adverse effects. Aust Fam Physician. 2011 Sep;40(9):705-8.
  38. Heidelbaugh JJ, Goldberg KL, Inadomi JM. Overutilization of proton pump inhibitors: a review of cost-effectiveness and risk [corrected]. Am J Gastroenterol. 2009 Mar;104 Suppl 2:S27-32.
  39. Roulet L, Vernaz N, Giostra E, Gasche Y, Desmeules J. Adverse effects of proton pump inhibitors: Should we worry about long-term exposure?. Rev Med Interne. 2012 Aug;33(8):439-45.
  40. El-Serag HB. Time trends of gastroesophageal reflux disease: a systematic review. Clin Gastroenterol Hepatol. 2007 Jan;5(1):17-26.
  41. Falk GW, Jacobson BC, Riddell RH, et al. Barrett’s esophagus: prevalence-incidence and etiology-origins. Ann N Y Acad Sci. 2011 Sep;1232:1-17.
  42. Thrift AP, Pandeya N, Whiteman DC. Current status and future perspectives on the etiology of esophageal adenocarcinoma. Front Oncol. 2012;2:11. Epub 2012 Feb 13.